Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of cabazitaxel丨cas 183133-96-2 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications
| Appearance | White or almost white crystalline powder |
| Purity (HPLC) | 99% min |
| Specific rotation | -39.0 ~ -45.0° |
| Loss on drying | 1% max |
| Water | 1% max |
| Identification (HPLC) | The retention time of the major peak in the chromatogram of the assay preparation corresponds to that in the chromatogram of the standard, as obtained in the assay |
| Identification (IR) | The IR spectrum of sample corresponds to that of reference standard |
| Related substance - Any unknown single impurity | 0.2% max |
| Related substance - Total impurities | 1% max |
| Residual Solvents - Ethanol | 0.5% max |
| Residual Solvents - Methanol | 0.3% max |
| Residual Solvents - Dichloromethane | 0.06% max |
| Residual Solvents - N-Hexane | 0.029% max |
| Residual Solvents - Acetic Ether | 0.5% max |
| Residual Solvents - Acetone | 0.5% max |
| Residual Solvents - THF | 0.072% max |
| Residual Solvents - Heptane | 0.5% max |
| Residue on ignition | 0.2% max |
| Heavy metals | 20 ppm max |
Transport Information
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2942000000313 |
|
Stability & Reactivity |
The product is chemically stable under standard ambient conditions. |
|
Storage |
Keep container tightly closed. Store in a cool and shaded area. Store locked up. |
|
Condition to Avoid |
|
|
Package |
Manufacturing Information
|
Parameter |
Specification |
|
Capacity |
10kg/month |
|
Frequency |
|
|
Main Export Countries |
US, EU, India, Korea, Japan, Southeast Asia |
|
Capacity/Batch |
|
|
Experience |
Production since 2008 |
|
Stock |
Applications
Cabazitaxel is primarily used in oncology as a chemotherapeutic agent for treating metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously undergone treatment with docetaxel. It is administered intravenously in combination with prednisone or prednisolone. Cabazitaxel operates by inhibiting microtubule depolymerization, thereby disrupting cancer cell division and inducing cell death.
Benefits
Cabazitaxel has demonstrated a survival benefit in mCRPC patients who have progressed after docetaxel therapy, offering an alternative treatment option when other therapies are ineffective. Its efficacy in overcoming resistance mechanisms to first-line taxanes makes it a valuable component in second-line chemotherapy regimens.
Conclusion
Cabazitaxel is a second-generation taxane that provides a therapeutic option for patients with advanced prostate cancer unresponsive to initial treatments. Its role in extending survival underscores its significance in the oncological treatment landscape. However, its use requires careful monitoring due to potential side effects, including neutropenia and gastrointestinal disturbances.
